Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 11Neoplasm Metastasis 2HER2 Positive Metastatic Breast Cancer 2Urinary Bladder Neoplasms 1Oesophagogastric Cancer 1Neoplasms 1Invasive Breast Cancer 1HER2-positive Advanced Breast Cancer 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Diseases 1

Interventions

pyrotinib 4Capecitabine 4Lapatinib 2Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × HER2 Positive Metastatic Breast Cancer × Lapatinib × Clear all
NCT03080805 2020-06-18

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
240 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

NCT02422199 2018-07-09

A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown
128 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡